tbuckley/cabot-search huggingface dataset:
WED-304 HERACLIS_BLV_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D
Authors: Margarita Papatheodoridi, Vasileios Sevastianos, Kalliopi Zachou, Dimitrios Christodoulou, Ioannis Koskinas, Melanie Deutsch, Alexandra Alexopoulou, Ioannis Elefsiniotis, Christos Triantos, Eleni Gigi, Theodoros Androutsakos, Dimitrios Karagiannakis, Iliana Mani, Dimitrios Dimitroulopoulos, Maria Mela, Emmanouil Sinakos, Spyridon Michopoulos, Konstantinos Mimidis, Nikolaos Papadopoulos, Athanasios Kontos, Christos Ωeretanos, Dimitrios Lymberopoulos, George Giannoulis, Vasilios Papadimitropoulos, Evdoxia Avramopoulou, Spyridon Pantzios, Larisa Vasilieva, Hariklia Kranidioti, Emmanouil Koullias, Nikolaos Psychos, Paraskevi Fytili, Ioannis Vlachogiannakos, Evangelos Cholongitas, Spilios Manolakopoulos, Ioannis Goulis, George Dalekos, George Papatheodoridis
Journal: Journal of Hepatology (2025)
WED-311 Paediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis delta
Authors: Parag Kumar, Anna Mc Laughlin, Nieves Velez de Mendizabal, Luzelena Caro, Kathryn Kersey, Carolina Iglesias-Lopez, Joanna Koziara, Ana Ruiz-Garcia
Journal: Journal of Hepatology (2025)
THU-246 Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants
Authors: Edward J. Gane, Dana Tedesco, Frida Abramov, Scott Balsitis, Mario Cortese, David Pan, Teri Chew, Sarah Arterburn, Audrey Lau, Anu Osinusi
Journal: Journal of Hepatology (2025)
THU-254 First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models
Authors: Emily P. Thi, Sharie C. Ganchua, Christine L. Espiritu, Ingrid Graves, Christina Iott, Timothy Eley, Tilly Varughese, Varun Sharma, Fran Xu, Amanda Pohl, Andrew G. Cole, Gavin D. Heffernan, Seyma Ozturk, Troy O. Harasym, Angela M. Lam, Edward J. Gane, Michael J. Sofia, Karen D. Sims
Journal: Journal of Hepatology (2025)
SAT-287 Metabolic comorbidities are risk factors for adverse liver-related events in individuals with HIV-HBV on tenofovir-based antiretroviral therapy
Authors: Lesley Patmore, Anders Boyd, Colette Smit, Mark Claassen, Katalin Pogány, Dirk Posthouwer, Theodora de Vries-Sluijs, Berend van Welzen, Marc van der Valk, Milan J. Sonneveld
Journal: Journal of Hepatology (2025)
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study
Authors: Emma Bell, Annabelle Lemenuel-Diot, Maria Teresa Catanese, Cong Cheng, Farouk Chughlay, Jean-Christophe Hoflack, Matteo Metruccio, Karolin Rommel, Ruchi Upmanyu, Qiaoqiao Xie, Claire McGeown, Rémi Kazma
Journal: Journal of Hepatology (2025)
THU-256 The safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for up to 96 Weeks in untreated HBeAg-positive subjects with chronic hepatitis B virus infection
Authors: Jinlin Hou, Hong Ren, Xieer Liang, Xian Yu, Jia Xu, Edward J. Gane, Man-Fung Yuen, Kosh Agarwal, Min Wu, Kha Le, Thanh Van, Jen Rito, Lawrence Blatt, Sushmita Chanda, Tse-I Lin, Yanhua Ding
Journal: Journal of Hepatology (2025)
WED-286 Comparative renal safety of besifovir dipivoxil maleate and tenofovir disoproxil fumarate in chronic hepatitis B patients: insights from a nationwide cohort study
Authors: Hyun Bin Choi, Jae-Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Journal: Journal of Hepatology (2025)
TOP-265 Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D)
Authors: Elisabetta Degasperi, Maria Paola Anolli, Sara Monico, Mathias Jachs, Thomas Reiberger, Christoph Schramm, Hartmut Schmidt, Caroline Zöllner, Frank Tacke, Christopher Dietz-Fricke, Heiner Wedemeyer, Margarita Papatheodoridi, George Papatheodoridis, Uta Merle, Dominique Roulot, Pietro Lampertico
Journal: Journal of Hepatology (2025)
WED-292 A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver trasplants of untreated and Bulevirtide-treated patients with chronic hepatitis Delta
Authors: Elisabetta Degasperi, Clara Dibenedetto, Marco Maggioni, Dana Sambarino, Enrico Sguazzini, Floriana Facchetti, Maria Paola Anolli, Michele Sagasta, Sara Monico, Pierluigi Toniutto, Caroline Zöllner, Frank Tacke, Nasser Semmo, Maria Francesca Donato, Pietro Lampertico
Journal: Journal of Hepatology (2025)
SAT-302 Dynamics of HBsAg isoforms during up to 9 years in treated and untreated HBeAg-negative chronic hepatitis B patients
Authors: Maria Pfefferkorn, Friedrich-Linus Rößiger, Jonathan Seltmann, Madlen Matz-Soja, Piero Colombatto, Andrea Pinna, Thomas Berg, Dieter Glebe, Elisabetta Degasperi, Pietro Lampertico, Maurizia Brunetto, Florian van Bömmel
Journal: Journal of Hepatology (2025)
WED-317 Exploring predictive factors for treatment response to Bulevirtide in Delta-positive patients
Authors: Verdiana Zulian, Chiara Taibi, Elisa Biliotti, Alessia Rianda, Silvia Pauciullo, Martina de Sanctis, Giampiero D’Offizi, AnnaRosa Garbuglia
Journal: Journal of Hepatology (2025)
THU-259 Up to 18 months’ functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: B-Sure third report
Authors: Seng Gee Lim, Tarik Asselah, Gheorghe Diaconescu, Adrian Gadano, Sebastián Marciano, Giuliano Rizzardini, Tatiana Stepanova, Hyung Joon Yim, Man-Fung Yuen, Alexandra Walker, Jie Dong, Geoff Quinn, Isabelle Santhiapillai, Helene Plein, Sophia Hussain, Raju Gowda, Matthijs Broer, Melanie Paff, Dickens Theodore, Robert Elston, Marjan Hezareh
Journal: Journal of Hepatology (2025)
WED-308 Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response
Authors: Maurizia Brunetto, Soo Aleman, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatiana Stepanova, Amos Lichtman, Renee-Claude Mercier, Dmitry Manuilov, Mingyang Li, Julian Schulze zur Wiesch, Stefan Zeuzem, Heiner Wedemeyer, Pietro Lampertico
Journal: Journal of Hepatology (2025)
THU-243 SOLSTICE week 24 subgroup analysis: impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran
Authors: Alina Jucov, Tarik Asselah, Anca Streinu-Cercel, Edward J. Gane, Heiner Wedemeyer, Pietro Lampertico, Michael A. Chattergoon, Bria Bullard, Cheng Huang, Rima Acosta, Cara Pilowa, Todd Correll, Carey Hwang, Kosh Agarwal
Journal: Journal of Hepatology (2025)
WED-305 Quantification of plasma HDV RNA by three commercially available assays in untreated and Bulevirtide-treated real-life patients with CHD: Robogene 2.0 vs. Altostar vs. Eurobioplex EBX071
Authors: Maria Paola Anolli, Sara Uceda Renteria, Elisabetta Degasperi, Floriana Facchetti, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Roberta Soffredini, Sara Monico, Annapaola Callegaro, Pietro Lampertico
Journal: Journal of Hepatology (2025)
SAT-289-YI Scaling up treatment of chronic hepatitis B in Africa: 1-year results from a simplified public-sector treatment program in Ethiopia
Authors: Lasse Rossvoll, Hailemichael Desalegn, Fikadu Girma Gudissa, Dawit Brhane, Ahmed Hussen, Waqtola Cheneke, Asiya Jeylan, Esayas Gudina, Nega Berhe, Asgeir Johannessen
Journal: Journal of Hepatology (2025)
THU-240 30% of inactive HBsAg carriers achieved clinical cure at 48 weeks with Pegylated Interferon alpha-2b therapy: a multicenter real- world study (STARHB Project in China)- 2.5 years data update
Authors: Shan Ren, Jing Zhao, Sujun Zheng, Bingliang Lin, Yongfang Jiang, Faqing Ruan, Yan Huang, Yilan Zeng, Jiawei Geng, Haifang Cao, Wenhua Zhang, Ying Guo, Xiaorong Mao, Zhiliang Gao, Tianyuan Shi, YueYong Zhu, Zu-Jiang Yu, Xiaoping Wu, Qing Mao, Xiulan Xue, Yingli He, Jia Shang, Shuangsuo Dang, Haidong Zhao, Rongshan Fan, Jiangling Yang, Jainqi Lian, Haibing Gao, Xin-Yue Chen
Journal: Journal of Hepatology (2025)
WED-290 Effectiveness and renal safety following switching to tenofovir alafenamide in patients with chronic hepatitis B: Results from a five-year, multicenter cohort study
Authors: Eiichi Ogawa, Motoyuki Kohjima, Toshimasa Koyanagi, Kazufumi Dohmen, Aritsune Ooho, Akira Kawano, Norihiro Furusyo, Eiji Kajiwara, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Rie Sugimoto, Yasunori Ichiki, Takeshi Senju, Hiromasa Amagase, Masatake Tanaka, Makoto Nakamuta, Hideyuki Nomura, Jun Hayashi
Journal: Journal of Hepatology (2025)
SAT-311 Prevention of HBV mother to child transmission using HBV three dose and selective use of HBV BD and treatment of high viral load pregnant women in Uganda
Authors: Ponsiano Ocama, Samantha Hall, Julius Kiwanuka, Brian Lwanga, Joan Mutyoba, Viola Kasone, Rachel Beyagira, Alexis Voeller, Homie Razavi
Journal: Journal of Hepatology (2025)
SAT-314 HBV RNA ultra-deep sequencing as a tool for HBV genotyping and resistance monitoring in virologically-suppressed individuals with chronic hepatitis B infection
Authors: Emma Bell, Maria Teresa Catanese, Jean-Christophe Hoflack, Sunny Shen, Marc Sultan, Matteo Metruccio, Anna Maria Geretti, Rémi Kazma
Journal: Journal of Hepatology (2025)
WED-269 The annual incidence of HCV RNA positivity detected by rapid on- site RT PCR doesn’t decrease and remains relatively high over the last 3 years among drug users
Authors: Denis Ouzan, Camerlo Nicolas, Tallec Erwan, Dupuis Justine, Namouni Teresa, Blasi Bruno, Lebrun Maela, Stéphane Chevaliez
Journal: Journal of Hepatology (2025)
WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide
Authors: Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Maria Arantxa Horga, Janet Hammond
Journal: Journal of Hepatology (2025)
THU-216 A step toward eliminating recalls and follow-up testing: first australian implementation of hepatitis C RNA reflexive testing utilising a single blood sample collected in the emergency department setting
Authors: Julia Di Girolamo, David Prince, Alexander Prudence, Robert Porritt, Kiran Thapa, Melissa Bagatella, Sicha Manandhar, Hong Foo, Michael Maley, Miriam Levy
Journal: Journal of Hepatology (2025)
THU-232 Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir
Authors: Saeed Sadiq Hamid, Huma Qureshi, Asad Chaudhry, Saad Niaz, Beatrice Emmanouil, Hamzah Z. Farooq, Naheed Choudhry, Tesfa Alamneh, HepFreePak Consortium, Graham R. Foster
Journal: Journal of Hepatology (2025)
THU-226 Hepatitis C treatment in arterial hypertension is safe and highly effective: real-world study
Authors: Michał Brzdeèk, Piotr Rzymski, Dorota Zareèbska-Michaluk, Barbara Poniedziałek, Beata Lorenc, Hanna Berak, Włodzimierz Mazur, Justyna Janocha-Litwin, Magdalena Tudrujek-Zdunek, Marek Sitko, Jakub Klapaczynèski, Robert Flisiak
Journal: Journal of Hepatology (2025)
SAT-277 Accurate prediction of long-term hepatitis B surface antigen seroclearance with machine learning: prognostic and management implications
Authors: Rex Wan-Hin Hui, Victor Chun-Lam Wong, Karen Cheuk-Ying Ho, Trevor Kwan-Hung Wu, Ryan Hin-Man Leung, Lung Yi Loey Mak, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen
Journal: Journal of Hepatology (2025)
WED-295 Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: a single-centre retrospective study
Authors: Xiaochuan Diao, Qianjun Wu, Misi Gu, Fei Huang, Yue Chen, Yixuan Zhang, Qin Ning, Meifang Han
Journal: Journal of Hepatology (2025)
THU-210 Evaluation of transient elastography and platelets count for predicting hepatocellular carcinoma in patients with chronic hepatitis C and sustained virological response to direct-acting antivirals
Authors: Paula Guedes, Juliana Piedade, Hugo Perazzo, Livia Villela-Nogueira, Helena Peixoto, Gustavo Pereira, Lailiane Novaes, Miriam Chinzon, Joyce Roma, Flavia Fernandes, Cristiane Villela-Nogueira
Journal: Journal of Hepatology (2025)
Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events
Authors: Edward Jackson, Andrea Dennis, Naim Alkhouri, Niharika Samala, Raj Vuppalanchi, Arun J Sanyal, Mark Muthiah, Rajarshi Banerjee, Amitava Banerjee
Journal: Nature Medicine (2025)

Abstract Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease are common conditions associated with high mortality and morbidity, yet opportunities for integrated prevention are underinvestigated. We explored the association between impairment in the liver (defined by increased iron-corrected T1 (cT1) time) and/or heart (reduced left ventricular ejection fraction ≤ 50) and risk of experiencing cardiovascular- or liver-related events or all-cause mortality among 28,841 UK Biobank participants who underwent magnetic resonance imaging. Using Cox proportional hazard models, adjusted for age, sex, body mass index, type 2 diabetes and dyslipidaemia, we observed that cardiac impairment was associated with increased incidence of cardiovascular events (hazard ratio (HR) 2.3 (1.9–2.7)) and hospitalization (HR 2.1 (1.8–2.4)). Liver impairment was associated with incident cardiovascular hospitalization (cT1 ≥ 800 ms, HR 1.3 (1.1–1.5)), liver events (cT1 ≥ 875 ms, HR 9.2 (3.2–26) and hospitalization (cT1 ≥ 875 ms, HR 5.5 (3.2–9.3). Associations between cT1 and liver events were maintained in participants with metabolic dysfunction-associated steatotic liver disease ( N = 6,223). Reduced left ventricular ejection fraction (≤50) combined with elevated cT1 (≥800 ms) were associated with earlier cardiovascular events (time to event 0.8 versus 2.4 years; P &lt; 0.05). Cardiac and liver impairment are independently, or in combination, associated with cardiovascular or liver events, suggesting a dual role for magnetic resonance imaging in integrated prevention pathways.
SAT-263 Enhancing hepatitis delta virus detection in Spain with the Delta Double Reflex (DDR) study
Authors: María Asunción Iborra, Beatriz Castro Hernández, Susana Rojo Alba, Berta Becerril Carral, Marta Lerate Alba, Carolina Freyre, Gonzalo Rivas Hernández, Sonia Algarate Cajo, Pablo Fraile Ribot, Miriam Blasco, María Carmen Lozano Domínguez, Waldo Sanchez-Yebra, Paloma Liendo, Maria Jesus Del Amor Espin, Sonsoles Garcinuño Pérez, Yasmina Martin, Maria Aroca, Maria Lourdes Molina, Pablo Fernández, Margarita Cámara, María José López de Goikoetxea, María Luz Núñez, María García Valero, Esther Manrique González, Antonio Puerta, César Gómez, Inocencio Beltrán Cifuentes, Pilar Álvarez Sastre, Marta Sandoval Torrientes, Alicia Beteta López, Susana García-De Cruz, Ruth Saez, María José Pena, Federico García, A. Aguilera
Journal: Journal of Hepatology (2025)
WED-260 Plasma exchange to treat hepatitis A related acute liver failure – a retrospective multicentre cohort study
Authors: Asisha M. Janeela, Shalimar Shalimar, Ramit Mahajan, Ajay Jain, Mayank Kabrawala, Mathew Philip, P.L. Alagammai, Ajith Kuriakose, Anand Sharma, Ajit Sood, Sohini Sircar, Sankalp Parikh, Prakash Zacharias, Domakuntala Amarnath, Suja Geevarghese, Gita Negi, Rajesh Kumar, Alka Jain, Remi Remakanth, Parshotam Gautam, Arshdeep Singh, Mustafa Malvi, Dolly Daniel, Uday Zachariah, Ashish Goel, CE Eapen
Journal: Journal of Hepatology (2025)
SAT-260 Autoimmunity in chronic hepatitis D: results from the HDV describe study cohort
Authors: Eleonora Dileo, Gian Paolo Caviglia, Tilde Manetta, Barbara Donati Marello, Paola Merlach, Alessandro Loglio, Mauro Viganò, Stefano Fagiuoli, Piero Colombatto, Barbara Coco, Antonella Olivero, Yulia Troshina, Alessia Ciancio, Alfonso Galeota Lanza, Debora Angrisani, Raffaella Tortora, Giovan Giuseppe Di Costanzo, Carlo Magni, Spinello Antinori, Giuliano Rizzardini, Vincenzo Messina, Michele Milella, Annalisa Saracino, Matilde Quaranta, Silvia Taurian, Caterina Quarta, Giuseppe Cariti, Valentina Cossiga, Filomena Morisco, Silvia Cretella, Gabriella Verucchi, Elisa Biliotti, AnnaRosa Garbuglia, Giampiero D’Offizi, Rosa Cotugno, Michele Barone, Raffaele Cozzolongo, Ester Marina Cela, Elisabetta Falbo, Lorenzo Surace, Grazia Anna Niro, Marcello Feasi, Emanuele Pontali, Carmine Coppola, Rachele Rapetti, Mario Pirisi, Nicolina Capoluongo, Nunzia Cuomo, Alessandro Perella, Antonio Izzi, Teresa Santantonio, Francesco Tortorici, Vito Di Marco, Clelia Cosentino, Aldo Marrone, Mariantonietta Pisaturo, Nicola Coppola, Giuliana Cologni, Marco Rizzi, Francesco Barbaro, Anna Maria Cattelan, Ezio Fornasiere, Pierluigi Toniutto, Maria Pallozzi, Francesca Romana Ponziani, Marcello Dallio, Mario Romeo, Alessandro Federico, Raffaella Viganò, Luca Saverio Belli, Laura Rapisarda, Enrico Siciliano, Emanuele Bracciamà, Alfredo Risicato, Gaetano Bertino, Massimo Puoti, Alberto Civolani, Marco Distefano, Elisabetta Teti, Massimo Andreoni, Maria Paola Anolli, Pietro Lampertico, Tommaso Stroffolini, Maurizia Brunetto, Giulio Mengozzi, Mario Rizzetto
Journal: Journal of Hepatology (2025)
FRI-244 Analysis of intrahepatic cccDNA and HBV-DNA in patients with hepatocellular carcinoma attributed to non-HBV etiologies
Authors: Elena Vargas-Accarino, Thais Leonel, Monica Higuera, Maria Saez-Palma, Agnes Soriano-Varela, Maria Torrens, Sabela Lens, Ariadna Rando, Sofía Pérez-del-Pulgar, Beatriz Minguez, Maria Buti
Journal: Journal of Hepatology (2025)
SAT-253 DM type 2 is a significant risk factor for HCC and decompensation of liver disease in HBV s Ag positive patients
Authors: Assaf Issachar, Michal Cohen-Naftaly, Marius Brown, Iftah Akai, Ran Tur-Kaspa, Orly Sneh Arbib
Journal: Journal of Hepatology (2025)
WED-263 Hepatitis E virus persistence in cerebrospinal fluid: a rare phenomenon observed in immunosuppressed patients beyond 18 months post-viremia clearance under Ribavirin therapy
Authors: Swetha Chalissery, Maria Mader, Matthias Gelderblom, Thorben Fruendt, Francis Ayuk, Ricardo Kosch, Katja Weisel, Annika Wolski, Jürgen Gallinat, Martin Lambert, Samuel Huber, Ansgar W. Lohse, Moritz Waldmann, Julian Schulze zur Wiesch, Sven Pischke
Journal: Journal of Hepatology (2025)
TOP-283-YI Transition of immune tolerant to immune active chronic hepatitis B and potential implications for monitoring and treatment
Authors: Lisa M. van Velsen, Mai Kilany, Norah Terrault, Terry Cheuk-Fung Yip, Karen Cheuk-Ying Ho, Gabriele Ricco, Sabela Lens, Anna Lok, Marc Ghany, Elena Vargas-Accarino, Stephanie Narguet, Bettina E. Hansen, Tarik Asselah, Maria Buti, Yao-Chun (Holden) Hsu, Xavier Forns, Maurizia Brunetto, Wai-Kay Seto, Man-Fung Yuen, Grace Wong, Jordan J. Feld, Milan J. Sonneveld, Harry L.A. Janssen
Journal: Journal of Hepatology (2025)
Targeting inflammation with chimeric antigen receptor macrophages using a signal switch
Authors: Qi Cao, Yiping Wang, Jianwei Chen, Ruifeng Wang, Titi Chen, Brian Gloss, Scott A Read, Xuerong Wang, Vincent W S Lee, Leighton Clancy, Natasha M Rogers, Stephen I Alexander, Guoping Zheng, Di Yu, David C H Harris
Journal: Nature Biomedical Engineering (2025)

Abstract Chimeric antigen receptor (CAR) T-cell immunotherapy has shown great success in clinical cancer, bringing hope to apply CAR strategies to other clinical settings. Here we developed a CAR macrophage (CAR-M) that recognizes the major inflammatory molecule tumour necrosis factor (TNF) and activates an intracellular IL-4 signalling pathway, thereby programming engineered macrophages for an anti-inflammatory function. CAR-M therapy has exhibited efficacy in mouse models of both acute and chronic inflammatory diseases. In kidney ischaemia reperfusion injury (IRI), infused CAR-Ms switched to an anti-inflammatory phenotype in inflamed kidney and attenuated kidney IRI. The anti-inflammatory phenotype of infused CAR-Ms switched off during the recovery phase of kidney IRI, coinciding with the disappearance of TNF. In Adriamycin-induced nephropathy, a model of chronic inflammatory disease, infused CAR-Ms maintained an anti-inflammatory phenotype for several weeks in response to sustained high levels of TNF and improved kidney function and structure. CAR-Ms also effectively reduced tissue injury in another organ, the liver. Human anti-TNF CAR-Ms exhibit anti-inflammatory phenotype and function in response to TNF. The CAR-M design, using signal switching, holds promise for the treatment of a broad range of acute and chronic inflammatory diseases.
FRI-242 FXR agonists as broad-acting antivirals against HBV/HDV/HEV and other hepato(cyto)tropic viruses
Authors: Julie Lucifora, Roxanne Fouillé, Romain Barnault, Florentin Pastor, Eva Ogire, Anne-Flore Legrand, Vincent Lotteau, Raphaël Darteil, Eloi Verrier, Philip Meuleman, Cyrille Mathieu, Christophe Ramieère, David Durantel
Journal: Journal of Hepatology (2025)
Genome-wide association meta-analysis of age at onset of walking in over 70,000 infants of European ancestry
Authors: Anna Gui, Anja Hollowell, Emilie M Wigdor, Morgan J Morgan, Laurie J Hannigan, Elizabeth C Corfield, Veronika Odintsova, Jouke-Jan Hottenga, Andrew Wong, René Pool, Harriet Cullen, Siân Wilson, Varun Warrier, Espen M Eilertsen, Ole A Andreassen, Christel M Middeldorp, Beate St Pourcain, Meike Bartels, Dorret I Boomsma, Catharina A Hartman, Elise B Robinson, Tomoki Arichi, Anthony D Edwards, Mark H Johnson, Frank Dudbridge, Stephan J Sanders, Alexandra Havdahl, Angelica Ronald
Journal: Nature Human Behaviour (2025)

Abstract Age at onset of walking is an important early childhood milestone which is used clinically and in public health screening. In this genome-wide association study meta-analysis of age at onset of walking ( N = 70,560 European-ancestry infants), we identified 11 independent genome-wide significant loci. SNP-based heritability was 24.13% (95% confidence intervals = 21.86–26.40) with ~11,900 variants accounting for about 90% of it, suggesting high polygenicity. One of these loci, in gene RBL2 , co-localized with an expression quantitative trait locus (eQTL) in the brain. Age at onset of walking (in months) was negatively genetically correlated with ADHD and body-mass index, and positively genetically correlated with brain gyrification in both infant and adult brains. The polygenic score showed out-of-sample prediction of 3–5.6%, confirmed as largely due to direct effects in sib-pair analyses, and was separately associated with volume of neonatal brain structures involved in motor control. This study offers biological insights into a key behavioural marker of neurodevelopment.